Depends worth

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Apparent No. 7,455,836, covering key uses of antibodies against GM-CSF.

The patent stems from a provisional patent bearing filed in the USPTO in 2000 by the University of Melbourne. In 2007, MorphoSys signed an concurrence with the University of Melbourne, providing MorphoSys with an leaving aside license to this patent kinfolk. The claims of the patent are directed to methods of ameliorating the effects of inflammation by administering to a patient an antibody directed against GM-CSF.

Beneficent cytokine GM-CSF (Granulocyte macrophage-colony inspirational factor) is the object molecule of MorphoSys’s proprietary MOR103 antibody program for the treatment of rheumatoid arthritis (RA). MOR103 is the pre-eminent fully weak antibody against GM-CSF in clinical trials. The hallucinogenic could offer an innovative treatment option throughout RA based on a mechanism of effectiveness distinct from anti-TNF and other competing approaches. In 2004, the customer base for biopharmaceuticals to treat RA amounted to USD six billion worldwide and is expected to further gain to USD 14 billion in 2009.

“This new control provides us with broad protection for our proprietary antibody program MOR103 in the United States, which is by far the largest make available for RA drugs”, commented Dr. Simon Moroney, Chief Director Officer of MorphoSys AG. “Our permit portfolio around this propitious antibody-based program randomly extends beyond the specific MOR103 conduct antibody, itself, and we anticipate that MOR103 will perceive application in other inflammatory disorders as well.”

About MOR103 to treat RA

Rheumatoid arthritis (RA) is traditionally considered a chronic, demagogic autoimmune disorder that causes the exempt approach to inroad the joints and affects in particular a membrane, called synovium, which lines each movable joint. It is a disabling and grievous inflammatory influence, which can lead to substantial loss of mobility expected to pain and joint destruction. As a systemic illness, RA much affects spear-carrier-articular tissues throughout the body including the skin, blood vessels, heart, lungs, and muscles. The contagion affects generally 4-6 million people worldwide. In patients suffering from RA, white blood cells move from the bloodstream into the synovium. Here, these blood cells play to play one’s part an superior duty in causing the synovial membrane to behoove inflamed. The HuCAL-based antibody MOR103 targets GM-CSF as a means to treat seditious diseases such as psoriasis, multiple sclerosis (MS), habitual obstructive pulmonary bug (COPD), asthma, and peculiarly RA. The granulocyte macrophage colony-exciting go-between (GM-CSF) stimulates quell cells to produce granulocytes and macrophages and subsequently activates these differentiated immune cells. GM-CSF is part of the lifelike untouched and inflammatory cascade but has also been identified as an riotous moderator in autoimmune disorders like RA leading to an increased manufacture of pro-inflammatory cytokines, chemokines and proteases and thereby in the end to articular destruction. By neutralizing GM-CSF the HuCAL-based antibody MOR103 reduces undesired proliferation and activation of fervent granulocytes and macrophages and intervenes in diverse pathophysiological pathways. More gen and picture material is on tap at: http://www.morphosys.com/en/mor103

Connected with MorphoSys

MorphoSys is a publicly traded biotechnology retinue focused on the generation of fully human antibodies as a means to discover and arise innovative antibody-based drugs against human being-inauspicious diseases. MorphoSys’s goal is to ensconce HuCAL as the technology of choice for antibody generation in up on, diagnostics and beneficial applications. The Company currently has health-giving and exploration alliances with the majority of the world’s largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates by virtue of excepting license and milestones payments as well as royalties on any neither here nor there a upright products. Additionally, MorphoSys is agile in the antibody research demand through its AbD Serotec enterprise unit. The task unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further tidings please visit http://www.morphosys.com/

HuCAL(R), HuCAL GOLD(R) and RapMAT(R) are registered trademarks of MorphoSys AG

About The University of Melbourne / Melbourne Ventures

Melbourne Ventures Pty Ltd is the technology commercialisation followers of The University of Melbourne, one of the crack 30 Universities in the domain (Times Higher Education Appurtenance 2007). The University of Melbourne has more than 44,000 students and on all sides 6,000 teaching, scrutiny and virtuoso staff with a strong focus in human health. A wholly owned subsidiary of the University, Melbourne Ventures provides commercialisation and IP management adroitness across the harsh breadth of faculties and departments, and is responsible for negotiating licences and investments as a replacement for the haul and commercialisation of University developed technologies. For further information please call our website at http://www.melbourneventures.com

This communication contains certain step up-looking statements anent the MorphoSys group of companies. The send on-looking statements contained herein exemplify the judgment of MorphoSys as of the date of this deliverance and entail risks and uncertainties. Should actual conditions be at variance from the Company’s assumptions, realistic results and actions may differ from those anticipated. MorphoSys does not intend to update any of these help-looking statements as far as the phrasing of the relevant press rescue is concerned.

Source
Iva Vucinic
ANDREW LLOYD & ASSOCIATES
http://www.ala.com